• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16732 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Austrian Institute for Health Technology Assessment (AIHTA) Leadless cardiac pacemakers
2025     Austrian Institute for Health Technology Assessment (AIHTA) One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee
2025     Austrian Institute for Health Technology Assessment (AIHTA) Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation
2025     Austrian Institute for Health Technology Assessment (AIHTA) Drug-coated balloon catheter for the treatment of urethral strictures
2025     Austrian Institute for Health Technology Assessment (AIHTA) Islet cell transplantation for chronic pancreatitis, type 1 diabetes, with and without kidney transplantation
2025     NIHR Health Technology Assessment programme Determining optimal strategies for primary prevention of cardiovascular disease: a synopsis of an evidence synthesis study
2025     NIHR Health Technology Assessment programme Glycaemic control in labour with diabetes: GILD, a scoping study
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones: the PUrE RCTs
2025     NIHR Health Technology Assessment programme Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
2025     NIHR Health Technology Assessment programme Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT
2025     NIHR Health Technology Assessment programme OrthoticS for TReatment of symptomatic flat feet In CHildren (OSTRICH): a randomised controlled trial
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Suvanto Care Safety Service
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Orla INR Remote Monitoring
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Zoturi — Online Story-Based Support for youth and families
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Sotender application for allocating social services and health care gig work
2025     Austrian Institute for Health Technology Assessment (AIHTA) Trauma care: teaching recovery technique (TRT) to children and adolescent refugees. Systematic review and evaluation of Austrian TRT-Programme at AFYA
2025     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell therapy: updated effectiveness and safety results from real-world evidence: a systematic review
2025     NIHR Health Services and Delivery Research programme Implementation of link workers in primary care: synopsis of findings from a realist evaluation
2025     NIHR Health Technology Assessment programme Extracorporeal carbon dioxide removal for the treatment of acute hypoxaemic respiratory failure: the REST RCT
2025     Austrian Institute for Health Technology Assessment (AIHTA) Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease
2025     NIHR Health Technology Assessment programme BioImpedance Spectroscopy to maintain Renal Output: the BISTRO randomised controlled trial
2025     Austrian Institute for Health Technology Assessment (AIHTA) Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B
2025     NIHR Health Technology Assessment programme Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial
2025     NIHR Health Technology Assessment programme Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT
2025     NIHR Health Services and Delivery Research programme A digital intervention to improve mental health and interpersonal resilience for young people who have experienced online sexual abuse: the i-Minds non-randomised feasibility clinical trial and nested qualitative study
2025     NIHR Health Services and Delivery Research programme Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study
2025     NIHR Health Technology Assessment programme Cessation of smoking in people attending UK emergency departments: the COSTED RCT with economic and process evaluation
2025     NIHR Health Services and Delivery Research programme Centralisation of specialised healthcare services: a scoping review of definitions, types, and impact on outcomes
2025     National Institute for Health and Care Excellence (NICE) Pulsed–field ablation for atrial fibrillation. NICE interventional procedures guidance 806
2025     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 1077
2025     National Institute for Health and Care Excellence (NICE) Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1076
2025     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 1075
2025     National Institute for Health and Care Excellence (NICE) Mirikizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1080
2025     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 1081
2025     National Institute for Health and Care Excellence (NICE) Fruquintinib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 1079
2025     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal). NICE technology appraisal guidance 1084
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal). NICE technology appraisal guidance 1083
2025     National Institute for Health and Care Excellence (NICE) Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal). NICE technology appraisal guidance 1082
2025     National Institute for Health and Care Excellence (NICE) Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over. NICE technology appraisal guidance 1085
2025     NIHR Health Technology Assessment programme Feasibility, acceptability and appropriateness of laparoscopic versus abdominal hysterectomy for women and healthcare professionals: the LAVA trial qualitative process evaluation
2025     Health Information and Quality Authority (HIQA) Retiring a clinical guideline: rapid scoping review
2025     Health Information and Quality Authority (HIQA) Magnetic resonance-guided radiotherapy (MRgRT) evidence synthesis to support a generic justification decision
2025     NIHR Health Technology Assessment programme Digital augmentation of aftercare for patients with anorexia nervosa: the TRIANGLE RCT and economic evaluation
2025     NIHR Health Services and Delivery Research programme Understanding patient pathways to Mother and Baby Units: a longitudinal retrospective service evaluation in the UK
2025     NIHR Health Technology Assessment programme Variation within and between digital pathology and light microscopy for the diagnosis of histopathology slides: blinded crossover comparison study
2025     NIHR Health Services and Delivery Research programme Consequences, costs and cost-effectiveness of workforce configurations in English acute hospitals
2025     NIHR Health Technology Assessment programme Melatonin versus midazolam in the premedication of anxious children attending for elective surgery under general anaesthesia: the MAGIC non-inferiority RCT
2025     NIHR Health Technology Assessment programme Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation
2025     NIHR Health Technology Assessment programme The risks, benefits, and resource implications of different diets in gastrostomy-fed children: The YourTube mixed method study
2025     NIHR Health Technology Assessment programme Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT
2025     NIHR Health Technology Assessment programme Ambulatory oxygen for pulmonary fibrosis (OxyPuF): a randomised controlled trial and acceptability study
2025     NIHR Health Technology Assessment programme Challenges to overcome in a randomised trial for Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in women: the PURSUIT RCT
2025     NIHR Health Technology Assessment programme Identifying optimal primary prevention interventions for major cardiovascular disease events and all-cause mortality: a systematic review and hierarchical network meta-analysis of RCTs
2025     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. NICE interventional procedures guidance 803
2025     National Institute for Health and Care Excellence (NICE) Targeted muscle reinnervation for managing limb amputation pain. NICE interventional procedures guidance 804
2025     National Institute for Health and Care Excellence (NICE) Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. NICE interventional procedures guidance 805
2025     National Institute for Health and Care Excellence (NICE) Somapacitan for treating growth hormone deficiency in people 3 to 17 years. NICE technology appraisal guidance 1066
2025     National Institute for Health and Care Excellence (NICE) Efgartigimod for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1069
2025     National Institute for Health and Care Excellence (NICE) Linzagolix for treating symptoms of endometriosis. NICE technology appraisal guidance 1067
2025     National Institute for Health and Care Excellence (NICE) Spesolimab for treating generalised pustular psoriasis flares. NICE technology appraisal guidance 1070
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2025     National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1071
2025     National Institute for Health and Care Excellence (NICE) Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. NICE technology appraisal guidance 1073
2025     National Institute for Health and Care Excellence (NICE) Sparsentan for treating primary IgA nephropathy. NICE technology appraisal guidance 1074
2025     National Institute for Health and Care Excellence (NICE) Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal). NICE technology appraisal guidance 1078
2025     Institute of Health Economics (IHE) PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025     NIHR Health Services and Delivery Research programme Community and hospital-based healthcare professionals perceptions of digital advance care planning for palliative and end-of-life care: a latent class analysis
2025     NIHR Health Technology Assessment programme The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
2025     Health Technology Wales (HTW) Smartphone based photoplethysmography for the detection and monitoring of atrial fibrillation
2025     NIHR Health Services and Delivery Research programme How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025     Agency for Care Effectiveness (ACE) Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025     Agency for Care Effectiveness (ACE) Atogepant and rimegepant for prophylaxis of migraine
2025     Agency for Care Effectiveness (ACE) Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Agency for Care Effectiveness (ACE) Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025     Agency for Care Effectiveness (ACE) Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025     NIHR Health Services and Delivery Research programme Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025     NIHR Health Services and Delivery Research programme Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025     NIHR Health Services and Delivery Research programme After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025     NIHR Health Services and Delivery Research programme The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025     NIHR Health Technology Assessment programme Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
2025     NIHR Health Technology Assessment programme Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis
2025     National Institute for Health and Care Excellence (NICE) Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal). NICE technology appraisal guidance 1061
2025     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 1059
2025     National Institute for Health and Care Excellence (NICE) Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025     National Institute for Health and Care Excellence (NICE) Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025     National Institute for Health and Care Excellence (NICE) Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025     National Institute for Health and Care Excellence (NICE) Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     NIHR Health Services and Delivery Research programme Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025     NIHR Health Services and Delivery Research programme Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025     NIHR Health Technology Assessment programme Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025     NIHR Health Technology Assessment programme Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025     NIHR Health Services and Delivery Research programme Implementing routine assessment of perinatal anxiety: case studies
2025     NIHR Health Services and Delivery Research programme How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025     Health Information and Quality Authority (HIQA) Evidence review of specialist cardiac services
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma